About Akebia Therapeutics
Akebia Therapeutics is a company based in Cincinnati (United States) founded in 2007.. Akebia Therapeutics has raised $91 million across 5 funding rounds from investors including Genechem, Kearny Venture Partners and Venture Investors. The company has 181 employees as of December 31, 2024. Akebia Therapeutics offers products and services including FDA-Approved Products. Akebia Therapeutics operates in a competitive market with competitors including Calliditas Therapeutics, Enyo Pharma, Unicycive, Alebund and Aurinia Pharmaceuticals, among others.
- Headquarter Cincinnati, United States
- Employees 181 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Akebia Therapeutics, Inc.
-
Annual Revenue
$160.18 M-17.7as on Dec 31, 2024
-
Net Profit
$-69.41 M-33.67as on Dec 31, 2024
-
EBITDA
$-8.71 M-106.01as on Dec 31, 2024
-
Total Equity Funding
$91 M (USD)
in 5 rounds
-
Latest Funding Round
$55 M (USD), Debt – Conventional
Jan 30, 2024
-
Investors
Genechem
& 9 more
-
Employee Count
181
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Akebia Therapeutics
Akebia Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AKBA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Akebia Therapeutics
Akebia Therapeutics offers a comprehensive portfolio of products and services, including FDA-Approved Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments addressing complications of chronic kidney disease
Unlock access to complete
Unlock access to complete
Leadership Team
31 people
Senior Team
17 people
Operations Team
10 people
Sales and Marketing
10 people
Software Development Team
9 people
Finance and Accounting
8 people
Board Team
6 people
Key Team
6 people
Unlock access to complete
Funding Insights of Akebia Therapeutics
Akebia Therapeutics has successfully raised a total of $91M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $55 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Debt – Conventional — $55.0M
-
First Round
First Round
(16 Jun 2010)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Debt – Conventional - Akebia Therapeutics | Valuation |
investors |
|
| Jun, 2013 | Amount | Series C - Akebia Therapeutics | Valuation |
investors |
|
| Apr, 2011 | Amount | Series B - Akebia Therapeutics | Valuation | Genechem |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Akebia Therapeutics
Akebia Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Genechem, Kearny Venture Partners and Venture Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is invested in US life sciences companies.
|
Founded Year | Domain | Location | |
|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia
|
Founded Year | Domain | Location | |
|
US focused early stage venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Akebia Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Akebia Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Akebia Therapeutics Comparisons
Competitors of Akebia Therapeutics
Akebia Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Enyo Pharma, Unicycive, Alebund and Aurinia Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| domain | founded_year | HQ Location |
Therapeutics are developed for diseases with impaired kidney function.
|
|
| domain | founded_year | HQ Location |
Small molecule therapies for kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for various kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Akebia Therapeutics
Frequently Asked Questions about Akebia Therapeutics
When was Akebia Therapeutics founded?
Akebia Therapeutics was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Where is Akebia Therapeutics located?
Akebia Therapeutics is headquartered in Cincinnati, United States. It is registered at Cincinnati, Ohio, United States.
Who is the current CEO of Akebia Therapeutics?
John Butler is the current CEO of Akebia Therapeutics.
Is Akebia Therapeutics a funded company?
Akebia Therapeutics is a funded company, having raised a total of $91M across 5 funding rounds to date. The company's 1st funding round was a Series B of $22M, raised on Jun 16, 2010.
How many employees does Akebia Therapeutics have?
As of Dec 31, 2024, the latest employee count at Akebia Therapeutics is 181.
What is the annual revenue of Akebia Therapeutics?
Annual revenue of Akebia Therapeutics is $160.18M as on Dec 31, 2024.
What does Akebia Therapeutics do?
Akebia Therapeutics was founded in 2007 and is headquartered in Cincinnati, United States. Operations are centered on the biotechnology sector, with a focus on developing therapeutic solutions for patients with kidney disease. The lead product, Vafseo, has been approved for treating anemia associated with chronic kidney disease in adults, covering both dialysis-dependent and non-dialysis-dependent cases. Research and development efforts continue to address unmet needs in renal care.
Who are the top competitors of Akebia Therapeutics?
Akebia Therapeutics's top competitors include Calliditas Therapeutics, Enyo Pharma and Alebund.
What products or services does Akebia Therapeutics offer?
Akebia Therapeutics offers FDA-Approved Products.
Is Akebia Therapeutics publicly traded?
Yes, Akebia Therapeutics is publicly traded on NASDAQ under the ticker symbol AKBA.
Who are Akebia Therapeutics's investors?
Akebia Therapeutics has 10 investors. Key investors include Genechem, Kearny Venture Partners, Venture Investors, Athenian Venture Partners, and Triathlon Medical Ventures.
What is Akebia Therapeutics's ticker symbol?
The ticker symbol of Akebia Therapeutics is AKBA on NASDAQ.